TOP特許意匠商標
商標ウォッチ Twitter
公開日2025-03-27
公報種別公開国際商標公報
国際登録番号1834844
国際登録日2024-11-13
区分第5類(薬剤),第42類(科学・技術)
商品役務Pharmaceutical products; biotechnological products for medical purposes; therapeutic drugs and active ingredients; pharmaceutical preparations for the treatment and/or prevention of cancer; biopharmaceuticals for the treatment and/or prevention of cancer; pharmaceutical preparations for the treatment and/or prevention of autoimmune and inflammatory diseases; pharmaceutical preparations for the treatment and/or prevention of skin diseases (dermatology), neurodegenerative and metabolic diseases.,Research and development services in the field of biotechnology; Research for medical purposes in the field of cancer, autoimmune and inflammatory diseases, skin diseases (dermatology), neurodegenerative and metabolic diseases.
基礎出願番号
基礎出願日
基礎出願国
出願人Monte Rosa Therapeutics AG
OCRテキスト
OCRテキスト2
OCRについて
この商標をJ-PlatPatで参照する

関連商標

Bayer Consumer Care AG
BEPANTHEN
3か月前
Orion Corporation
ORIONPHARMA
4か月前
ROXALL Medizin GmbH
SULGEN
2か月前
ROXALL Medizin GmbH
1か月前
JADRAN - GALENSKI LABORATORIJ d.d.
MERALYS
5か月前
Novartis AG
OJUVIP
8か月前
個人
GI-MASK
10か月前
Triticum Exploitatie B.V.
L-MESITRAN
7か月前
BOLERO & Co Ltd.
BOLERO
7か月前
ROXALL Medizin GmbH
ROXALL
2か月前
COSWELL S.p.A.
BLANX
10か月前
個人
SPEEDEX
6か月前
AFT PHARMACEUTICALS LIMITED
Kiwisoothe
10か月前
NOVARTIS AG
DYNTIMIC
10か月前
NOVARTIS AG
REGNYTIM
10か月前
NOVARTIS AG
INTYMGO
10か月前
Aston Group Worldwide Ltd
INESSA
3か月前
BRILL ENGINES, S.L.
Brillengines
5か月前
Novartis AG
1か月前
Premier Foods Group Limited
FUEL10K
10か月前
Biohaven Therapeutics Ltd.
REJUTRIA
3か月前
Novartis AG
2か月前
Novo Nordisk A/S
Zilconyc
8か月前
Applied Nutrition Limited
APPLIED NUTRITION
11か月前
Novartis AG
2か月前
NOVARTIS AG
ENGIVYV
2か月前
NOVARTIS AG
EINGEFYR
2か月前
Made By Brave Limited
3か月前
NOVARTIS AG
STIMESQUE
10か月前
NOVARTIS AG
1か月前
NOVARTIS AG
1か月前
OLIVIT Sp. z o.o.
osavi
7か月前
BRILL INTERNATIONAL, S.L.
3か月前
INTERSALES COMPANY, naamloze vennootschap
FORNATURAL ENERGY MALT DRINK AND VITALITY
10か月前
NOVARTIS AG
1か月前
ROXALL Medizin GmbH
1か月前
続きを見る